The Association of Community Cancer Centers announced the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies.
The Association of Community Cancer Centers (ACCC) announced the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies. ACCC worked closely with a team of multispecialty thought leaders via the IO Institute Working Groups to develop forward-thinking resources at the intersection of clinical science, care delivery, business, operations, and policy to support all facets of immunotherapy integration.
The ACCC Immuno-Oncology Institute is the only initiative dedicated to educating multidisciplinary teams to go beyond a clinical understanding of IO and tackle real-world implementation issues. With the care of patients on immunotherapies now extending beyond the cancer team, the ACCC Immuno-Oncology Institute is at the forefront of developing critical education to empower healthcare professionals across care delivery settings.
“As IO has advanced at a rapid pace, there was a need to evolve our Institute,” said Lee S. Schwartzberg, MD, FACP Chair, ACCC IO Institute Executive Committee. “From quick takeaways to a thought-provoking "Immuno-Oncology Insights" series; eLearning courses, webinars, and videos; and our comprehensive, end-of-year publication, the ACCC Immuno-Oncology Institute is developing an extensive collection of operational, clinical, and administrative tools that are designed to meet professional interests and demanding schedules.”
Resources available on the ACCC Immuno-Oncology Institute web portal address the following topics:
The ACCC Immuno-Oncology Institute is supported by Bristol-Myers Squibb; EMD Serono; Kite, a Gilead Company; and Merck & Co, Inc.